Overview

A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors

Status:
Completed

Trial end date:
2014-08-01

Target enrollment:

Participant gender:

Summary

This is a Phase I, first-in-human, open label, dose-escalation study of MINT1526A administered alone and in combination with bevacizumab by IV infusion every 3 weeks to patients with advanced solid tumors for whom standard therapy either does not exist or has proven to be ineffective or intolerable.

Phase:

Phase 1

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Bevacizumab